Yuichi Tomidokoro

Dr. Yuichi Tomidokoro

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Auris Nasus Larynx
Verified
Journal Article
Closed access
YTYuichi Tomidokoro
Yuichi Tomidokoro
RHRyuichi Hayashi
Ryuichi Hayashi
MYMitsuo Yamasaki
Mitsuo Yamasaki
GIGenichiro Ishii
Genichiro Ishii
TKTomoyuki Kamijo
Tomoyuki Kamijo
SESatoshi Ebihara
Satoshi Ebihara

Verified
Journal Article
Open access
PDF file
KCKazuaki Chikamatsu
Kazuaki Chikamatsu
HTHideyuki Takahashi
Hideyuki Takahashi
HTHiroe Tada
Hiroe Tada
MUMiho Uchida
Miho Uchida
SIShota Ida
Shota Ida
Masaomi MotegiMasaomi Motegi
Masaomi Motegi
The detection of circulating tumor cells (CTCs) using immunoaffinity-based methods often relies on epithelial-related markers, which may bias the selection of CTCs and limit the biological information obtained, depending on the targeted antigens. Herein, we compared the molecular profiles and clinical significance of CTCs based on the expression of epithelial-related markers (EPCAM, EGFR, and MET) in patients with head and neck squamous-cell carcinoma (HNSCC). CTCs were detected using density gradient separation and CD45-negative selection, followed by quantitative PCR for epithelial-related marker expression. Expression profiles of epithelial–mesenchymal transition (EMT)-related (VIM, CDH1, CDH2, SNAI1, ZEB1, ZEB2, and TWIST1) and immune-regulatory (CD274 and PDCD1LG2) genes were compared. Moreover, the association between marker expression and clinical factors was analyzed. Among the 60 patients with CTCs, 48 (80.0%), 20 (33.3%), and 31 (51.7%) were positive for EPCAM, EGFR, and MET, respectively. A significant correlation was observed between CTCs expressing EPCAM and EGFR. CTCs expressing distinct markers showed differing EMT-related and immune-regulatory gene expression. EPCAM+ CTCs were associated with advanced-stage disease, while EGFR+ CTCs were correlated with locoregional relapse and shorter progression-free survival (p = 0.007; hazard ratio = 3.254). Patients with EPCAM/EGFR double-positive CTCs had the poorest prognosis. These findings emphasize the importance of marker selection in liquid biopsy technologies and highlight the need for improved detection methods and the further investigation of CTC biology.

30 January 2025 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
AMAtsushi Musha
Atsushi Musha
NKNobuteru Kubo
Nobuteru Kubo
HKHidemasa Kawamura
Hidemasa Kawamura
NONaoko Okano
Naoko Okano
MOMasahiro Onishi
Masahiro Onishi
TOTatsuya Ohno
Tatsuya Ohno
Despite recognizing the effectiveness of carbon-ion radiotherapy (C-ion RT) in treating head and neck adenoid cystic carcinoma (HN-ACC), the impact of perineural tumor spread (PNTS) on treatment outcomes and the relationship between PNTS and post-treatment marginal recurrences remain unexplored. Therefore, we analyzed the efficacy of C-ion RT in HN-ACC, focusing on PNTS including details of post-treatment marginal recurrence and indicators for future treatment strategies. In this retrospective study, we included 74 patients diagnosed with HN-ACC who underwent C-ion RT between June 2010 and July 2022. Treatment dosages were either 57.6 or 64.0 Gy (relative biological effectiveness) delivered in 16 fractions. Patients undergoing C-ion RT were identified retrospectively from medical records. PNTS was evaluated by magnetic resonance imaging for detecting extratumoral extension to peritumoral nerves. The median duration of follow-up was 46.4 months. Local recurrence developed in 19 patients. Moreover, most marginal recurrences occurred within the irradiated margins. The 5-year rates for local control (LC), progression-free survival (PFS), and overall survival (OS) were 67.6 %, 47.7 %, and 79.0 %, respectively. LC (p = 0.005) and PFS (p = 0.013) demonstrated significant variances on analysis based on PNTS occurrence; however, OS did not exhibit a similar pattern. Our findings highlight the importance for considering disease-specific characteristics and the need for developing targeted strategies that address the complex nature of HN-ACC, particularly in cases involving PNTS, to enhance treatment outcomes and potentially reduce recurrence rates.

8 October 2025 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
TMToshiyuki Matsuyama
Toshiyuki Matsuyama
RKReika Kawabata-Iwakawa
Reika Kawabata-Iwakawa
HTHideyuki Takahashi
Hideyuki Takahashi
YTYuichi Tomidokoro
Yuichi Tomidokoro
Masaomi MotegiMasaomi Motegi
Masaomi Motegi
KCKazuaki Chikamatsu
Kazuaki Chikamatsu
Nasal polyps (NP) contribute to treatment resistance in chronic rhinosinusitis with nasal polyps (CRSwNP); however, the cellular and molecular mechanisms underlying nasal polypogenesis are not completely understood. To investigate whether the characteristics of fibroblasts differ under the surrounding tissue environment. Patients with CRSwNP were divided into two groups based on the eosinophil infiltration in the NP; the gene expression levels were evaluated. Fibroblasts established from NP were assessed for functional changes following cytokine stimulation, and RNA sequencing (RNA-seq) was performed. IL5 and IL13 expression was higher, and IFNG and TNF lower, in NP from eosinophilic CRS (ECRS) patients compared to non-ECRS. FOXP3 expression was significantly upregulated in ECRS patients. Cytokine-stimulated fibroblasts from both ECRS and non-ECRS showed similar expression of fibroblast-to-myofibroblast transition-related genes and significantly reduced migratory capacity following IL-13 and TNF-α treatment. RNA sequencing revealed six and thirty-five significant activated and inactivated signaling pathways, respectively, in the Diseases Bio Functions analysis. Fibroblasts contribute to nasal polypogenesis irrespective of inflammation type in CRSwNP. Although their behavior is regulated by the immune microenvironment, our findings also highlight fibroblasts as potential therapeutic targets, supporting both endotypic classification and novel treatment strategies.